KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Free Cash Flow for 6 consecutive years, with -$44.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 88.68% year-over-year to -$44.6 million, compared with a TTM value of -$174.1 million through Dec 2025, up 6.89%, and an annual FY2025 reading of -$174.1 million, up 6.89% over the prior year.
  • Free Cash Flow was -$44.6 million for Q4 2025 at AbCellera Biologics, up from -$61.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $241.7 million in Q2 2022 and bottomed at -$139.3 million in Q3 2022.
  • Average Free Cash Flow over 5 years is -$4.5 million, with a median of -$24.9 million recorded in 2021.
  • Peak annual rise in Free Cash Flow hit 7961.99% in 2021, while the deepest fall reached 11570.54% in 2021.
  • Year by year, Free Cash Flow stood at -$26.1 million in 2021, then soared by 171.08% to $18.6 million in 2022, then plummeted by 283.2% to -$34.0 million in 2023, then surged by 30.59% to -$23.6 million in 2024, then crashed by 88.68% to -$44.6 million in 2025.
  • Business Quant data shows Free Cash Flow for ABCL at -$44.6 million in Q4 2025, -$61.5 million in Q3 2025, and -$45.8 million in Q2 2025.